Roquefort Therapeutics (LON:ROQ) Shares Down 4.5% – Here’s What Happened

Roquefort Therapeutics plc (LON:ROQ)’s stock price was down 4.5% on Friday . The stock traded as low as GBX 2 ($0.03) and last traded at GBX 2.10 ($0.03). Approximately 2,318,495 shares changed hands during trading, an increase of 10% from the average daily volume of 2,110,917 shares. The stock had previously closed at GBX 2.20 ($0.03).

Roquefort Therapeutics Price Performance

The stock’s 50 day simple moving average is GBX 1.66 and its 200-day simple moving average is GBX 1.66. The firm has a market cap of £3.31 million, a price-to-earnings ratio of -280.00 and a beta of 0.05. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79.

Insider Activity

In other news, insider Stephen Paul West bought 2,400,000 shares of Roquefort Therapeutics stock in a transaction that occurred on Friday, July 4th. The stock was bought at an average price of GBX 2 per share, for a total transaction of £48,000. 20.35% of the stock is currently owned by insiders.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.